In poor responders and patients with PCOS, GnRH antagonist therapy has been proposed to be the first treatment protocol option [20]; however, a recent review article has also stated that a long GnRH agonist protocol is still applicable for poor responders [21]. The gene discussed is GNRH1; the disease is polycystic ovary syndrome.